home / stock / lxgtf / lxgtf news
VANCOUVER, British Columbia, April 16, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by ...
VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) provides the following corporate update to shareholders. HeartSentry Technology The Company had been unable to secure...
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) has allowed the license with the Lawrence Berkeley National Laboratories, which was being used in the HeartSentry technology, ...
VANCOUVER, British Columbia, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) announces that it has reached agreement with third parties as well as certain directors and officers (collectively the “...
VANCOUVER, British Columbia, April 02, 2019 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announced on February 14, 2019 that it had been unable to secure the necessary financing to advance the develo...
VANCOUVER, British Columbia, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that, despite numerous attempts over the past 9 months, it has been unable to secure the necessary fu...
News, Short Squeeze, Breakout and More Instantly...
Lexington Biosciences Inc Company Name:
LXGTF Stock Symbol:
OTCMKTS Market:
Lexington Biosciences Inc Website:
VANCOUVER, British Columbia, April 16, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) is pleased to announce the appointment of Donald McInnes as chief executive officer of the Company, filing the vacancy left by ...
VANCOUVER, British Columbia, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) provides the following corporate update to shareholders. HeartSentry Technology The Company had been unable to secure...
VANCOUVER, British Columbia, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) has allowed the license with the Lawrence Berkeley National Laboratories, which was being used in the HeartSentry technology, ...